Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sandra X. Franco"'
Autor:
Fatima Cardoso, Shani Paluch-Shimon, Eva Schumacher-Wulf, Leonor Matos, Karen Gelmon, Matti S. Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chavez-MacGregor, Runcie Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca A. Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda Kiely, Sung-Bae Kim, Smruti Koppikar, Marion J.J. Kuper-Hommel, Frédéric E. Lecouvet, Ginny Mason, Shirley A. Mertz, Volkmar Mueller, Claire Myerson, Silvia Neciosup, Birgitte V. Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault-Llorca, Aleix Prat, Hope S. Rugo, Elzbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel A. Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer
Publikováno v:
Breast, Vol 76, Iss , Pp 103756- (2024)
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Globa
Externí odkaz:
https://doaj.org/article/de357938368a491d8c29ea9020d3b42e
Autor:
Alejandra T. Perez, William V. Williams, Simon Turner, Robert A. Somer, Francisco J. Esteva, A. Florance, Sandra X. Franco, S. Stein, Maura K. Hagan, Abenaa M. Brewster
Publikováno v:
The Oncologist. 18:661-666
Background. Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC)
Autor:
Ben Nulsen, M. Arbushites, Sandra X. Franco, Janet H. Scott, John W. Park, Hope S. Rugo, Soumi Lahiri, Alexa Glencer, Alison Stopeck, Maura N. Dickler, Clifford A. Hudis, A. Jo Chien
Publikováno v:
Breast Cancer Research and Treatment
Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)--targeted agents has antitumor activity; these data indicate certain patients w
Autor:
Charles L. Vogel, Neil Abramson, James W. Jakub, Michael Schwartz, Grace Wang, Cynthia Frankel, Alisha Stein, Alejandra T. Perez, Sandra X. Franco, Elisa Krill-Jackson, Lee S. Schwartzberg, Aruna Mani, Elizabeth Tan-Chiu
Publikováno v:
Community Oncology. 8:209-215
Autor:
Sandra X. Franco, A. Florance, Lee S. Schwartzberg, J. Maltzman, Stephen R. D. Johnston, L. O'Rourke
Publikováno v:
The Oncologist
Reported are results from a subgroup analysis of postmenopausal women with hormone receptor–positive human epidermal growth factor receptor 2–positive metastatic breast cancer from a phase III trial of letrozole plus placebo versus letrozole plus
Publikováno v:
Breast Cancer Research and Treatment. 88:103-108
Fulvestrant ('Faslodex') is a new estrogen receptor (ER) antagonist that has no agonist effects. It binds, blocks and accelerates degradation of the ER, leading to a complete abrogation of estrogen-sensitive gene transcription. In postmenopausal wome
Autor:
Sandra X. Franco, Charles L. Vogel
Publikováno v:
The Breast Journal. 9:452-462
Trastuzumab is a humanized monoclonal antibody against the epidermal growth factor family oncogene, Her-2/neu. It has revolutionized therapy for the 15-20% of patients with metastatic breast cancer whose tumors have gene amplification for Her-2/neu.
Autor:
Stephen R. D. Johnston, Denise A. Yardley, Olivier Rixe, Miguel Martin, Sandra X. Franco, Stephen P. Letrent, Hope S. Rugo, Banu Arun
Publikováno v:
Cancer chemotherapy and pharmacology. 64(6)
To evaluate the efficacy and safety of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in metastatic breast cancer (MBC).Patients with measurable, progressive, or recurrent MBC whose primary tumor expressedor =1 ErbB receptor were randomized
Autor:
Dinesh C. Doval, Sandra X. Franco, George W. Sledge, Mark S. Berger, Louis W.C. Chow, Miguel A. Chavez, M. Arbushites, Shona Nag, Zeba Aziz, Michelle A. Casey, Peter Ang, Henry L. Gomez, Christina Ng, S. Stein
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(18)
Purpose This study ( EGF20009 ) assessed the efficacy and tolerability of two lapatinib administration schedules as first-line monotherapy in women with ErbB2-amplified locally advanced or metastatic breast cancer. Patients and Methods Patients with
Autor:
Emma Shtivelman, Michelle E. Melisko, Hope S. Rugo, Mary Tagliaferri, Sandra X. Franco, Alejandra T. Perez, Elizabeth Tan Chiu, Mark Shoemaker, Isaac Cohen, Debasish Tripathy, Zung Vu Tran, Charles L. Vogel
Publikováno v:
Breast cancer research and treatment. 105(1)
Botanical therapies are often used by breast cancer patients yet few clinical trials have evaluated their safety and efficacy. We studied mechanisms of activity and performed a phase I clinical trial in patients with advanced breast cancer to evaluat